530538 Sigma-AldrichcPLA2α Inhibitor II, Pyrrophenone - CAS 341973-06-6 - Calbiochem
A cell-permeable, highly potent, and reversible inhibitor of cytosolic phospholipase A2a (IC₅₀ = 4.2 nM).
More>> A cell-permeable, highly potent, and reversible inhibitor of cytosolic phospholipase A2a (IC₅₀ = 4.2 nM). Less<<Synonyms: Phospholipase A2α Inhibitor
Recommended Products
Overview
Replacement Information |
---|
Key Specifications Table
CAS # | Empirical Formula |
---|---|
341973-06-6 | C₄₉H₃₇F₂N₃O₅S₂ |
Pricing & Availability
Catalog Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
---|---|---|---|---|---|---|
5.30538.0001 |
|
Glass bottle | 1 mg |
|
— |
References | |
---|---|
References | Ono, T., et al. 2002. Biochem. J. 363, 727. Seno, K., et al. 2001. Bioorg. Med. Chem. Lett. 11, 587. |
Product Information | |
---|---|
CAS number | 341973-06-6 |
Form | Off-white powder |
Hill Formula | C₄₉H₃₇F₂N₃O₅S₂ |
Chemical formula | C₄₉H₃₇F₂N₃O₅S₂ |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | PLA2a |
Primary Target IC<sub>50</sub> | 4.2 nM |
Purity | ≥98% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalog Number | GTIN |
5.30538.0001 | 04055977260892 |
Documentation
cPLA2α Inhibitor II, Pyrrophenone - CAS 341973-06-6 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Ono, T., et al. 2002. Biochem. J. 363, 727. Seno, K., et al. 2001. Bioorg. Med. Chem. Lett. 11, 587. |
Brochure
Title |
---|
NPI Flyer- Epigenetics and Nuclear Function Feature |
New Products - Antibodies, Small Molecule, Inhibitors |
Technical Info
Title |
---|
White Paper: Further considerations of antibody validation and usage. |